BioCentury | Feb 24, 2018

Patients as pawns

In an apparent game of chicken between Vertex Pharmaceuticals Inc. and French health authorities over the price of the cystic fibrosis drug Orkambi, patients say the decision to use access to investigational therapies as a...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Extra | Jun 23, 2017
Clinical News

Novo’s semaglutide shows obesity benefit in Phase II trial

Data from a Phase II study to treat obesity showed subcutaneous semaglutide (NN9535) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) led to an estimated weight loss benefit of up to 13.8% vs. 2.3% for placebo, combined...
BioCentury | Mar 25, 2017

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
BioCentury | Sep 19, 2016
Product Development

Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can convince...
BC Week In Review | Sep 5, 2016
Clinical News

Trokendi XR topiramate regulatory update

FDA granted final approval to an sNDA from Supernus for Trokendi XR topiramate as monotherapy treatment of partial onset seizures in patients ages 6-9. The drug is approved for the indication in patients ages >=10....
BC Week In Review | Jun 27, 2016
Clinical News

Trokendi XR topiramate regulatory update

Supernus said FDA asked the company to resubmit its proposed label for Trokendi XR topiramate to prevent migraines in a different format as part of the agency’s review of an sNDA. Supernus plans to resubmit...
BioCentury | Mar 7, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/4 cls Orexigen Therapeutics Inc. (NASDAQ:OREX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -28% $0.70 Simeonidis also...
BC Week In Review | Nov 9, 2015
Company News

Supernus, Endo deal

Supernus granted Endo’s Par Pharmaceutical company rights to sell the generic version of Trokendi XR topiramate starting on April 1, 2025, settling patent litigation. Par had submitted an ANDA for approval of a generic version...
BioCentury | Oct 5, 2015

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are in the...
Items per page:
1 - 10 of 465